List of Excipients in Branded Drug MICONAZOLE 3

« Back to Dashboard

Generic Drugs Containing MICONAZOLE 3

Company	Ingredient	NDC	Excipient
Walgreen Company	miconazole nitrate	0363-2070	BENZOIC ACID
Walgreen Company	miconazole nitrate	0363-2070	CETYL ALCOHOL
Walgreen Company	miconazole nitrate	0363-2070	ISOPROPYL MYRISTATE

What are the Most Frequently-Used Excipients in MICONAZOLE 3?

# Of NDCs	Excipient
1	BENZOIC ACID
3	CETYL ALCOHOL
3	ISOPROPYL MYRISTATE

Miconazole 3 Excipient Strategy and Commercial Opportunities

Last updated: September 27, 2026

Miconazole 3 is a three-day vaginal antifungal product, generally containing miconazole nitrate 200 mg per dose. Its commercial opportunity is primarily in excipient optimization, delivery format, tolerability, packaging, private-label supply, and differentiated consumer positioning. The active ingredient is mature, and U.S. market access generally relies on the FDA over-the-counter vaginal antifungal framework rather than new-drug exclusivity.

What is Miconazole 3 and how is it regulated?

Miconazole 3 usually refers to a vaginal product administered once daily for three days. Common presentations include:

Product type	Typical miconazole nitrate content	Administration	Common market positioning
Vaginal suppository or ovule	200 mg per dose	One dose nightly for three nights	Established three-day therapy
Vaginal cream	2%	One applicator daily for three days	Cream-based alternative
Combination pack	200 mg vaginal doses plus external cream	Internal and external use	Itching and irritation support

Miconazole nitrate vaginal products are regulated in the United States under the FDA’s OTC vaginal antifungal drug framework. The FDA monograph permits specified antifungal active ingredients, concentrations, dosage forms, labeling, and directions without an individual product approval if the product complies with the applicable requirements.[1]

Miconazole 3 is generally positioned for vulvovaginal candidiasis caused by susceptible Candida species. Products commonly carry warnings for first-time symptoms, pregnancy, recurrent infections, abdominal pain, fever, chills, nausea, vomiting, foul-smelling discharge, and sexually transmitted infection concerns.[2]

FDA regulatory status

A compliant Miconazole 3 product typically requires:

• An eligible miconazole nitrate active ingredient.
• A permitted vaginal dosage form.
• Conforming strength and directions.
• Manufacturing under current good manufacturing practice requirements.
• Drug Facts labeling.
• Appropriate product listing and establishment registration.
• Stability, microbial quality, packaging, and performance data.

A reformulated product may remain within the OTC monograph if the active ingredient, dosage form, strength, route, indications, and labeling remain compliant. A novel delivery system, new indication, or materially different therapeutic claim may require an FDA regulatory pathway outside the monograph.

What excipients are used in Miconazole 3?

The excipient system depends on whether the product is a suppository, ovule, cream, tablet, or combination pack. Commercial miconazole vaginal suppositories commonly use a fatty or hydrogenated vegetable oil base. Cream products use an emulsion containing oil-phase ingredients, emulsifiers, water, preservatives, and viscosity modifiers.[2]

Typical excipient categories include:

Excipient function	Candidate materials	Commercial purpose
Suppository base	Hydrogenated vegetable oils, hard fats, synthetic triglycerides	Melting, drug release, product integrity
Cream oil phase	Mineral oil, fatty alcohols, esters, hydrocarbons	Spreadability and occlusion
Emulsifier	Nonionic surfactants, fatty alcohol blends	Emulsion stability
Thickener	Carbomers, cellulose derivatives, waxes	Residence time and handling
Humectant	Propylene glycol, glycerin, glycols	Moisture retention and texture
Preservative	Benzoic acid, parabens, phenoxyethanol, sorbate systems	Microbial control in water-containing products
Chelator	Disodium edetate	Preservative support and metal-ion control
Antioxidant	Butylated hydroxyanisole and related systems	Protection of oils and active ingredient
Packaging aid	Low-friction films, barrier laminates, molded applicators	Dose delivery and product stability

The final excipient selection must be assessed against vaginal tolerability, local irritation, osmolality, pH, preservative exposure, drug crystallization, leakage, and compatibility with the applicator and primary package. The FDA Inactive Ingredient Database can support precedent analysis, but prior use does not eliminate the need for formulation-specific safety and quality studies.[3]

What excipient strategy is strongest for Miconazole 3?

The strongest strategy is usually a short, well-precedented excipient system that improves handling and patient experience without introducing a novel clinical claim.

1. Optimize the suppository base

The suppository base controls:

• Melting behavior at body temperature.
• Release of miconazole nitrate.
• Leakage after insertion.
• Mechanical strength during shipping.
• Stability in warm climates.
• Ease of manufacture and demolding.

Hydrogenated vegetable oil systems are commercially familiar and can support low-cost production. Their main risks are polymorphism, batch-to-batch melting variation, rancidity, and temperature sensitivity. Synthetic hard-fat systems may provide tighter melting-point control and more reproducible release, but they can increase raw-material cost.

A differentiated product could use a base engineered for reduced leakage and improved overnight retention. The opportunity is commercially relevant because consumers often compare vaginal products based on mess, leakage, applicator convenience, and symptom relief rather than active ingredient alone.

2. Control drug release and residence time

Miconazole is poorly water soluble. The excipient system must balance dissolution with retention at the vaginal site. Excessively hydrophobic bases can slow release, while highly hydrophilic systems may dissolve quickly and leak.

Potential approaches include:

• Mixed lipid bases with controlled melting behavior.
• Bioadhesive polymers in cream or gel systems.
• Structured emulsions that resist rapid drainage.
• Particle-size control for miconazole nitrate.
• Surfactant systems that improve wetting without excessive irritation.

A release profile that supports once-nightly dosing is commercially attractive, but any claim implying superior efficacy or longer protection must be supported by appropriate product-performance and clinical data.

3. Reduce irritation risk

Vaginal products have a narrow tolerability margin. Excipients that are acceptable on skin may cause burning, dryness, or irritation intravaginally. A lower-irritation strategy should prioritize:

• Minimal fragrance and colorant use.
• Conservative surfactant levels.
• Controlled preservative exposure.
• Avoidance of unnecessary volatile solvents.
• Physiologically acceptable pH where relevant.
• Low osmolality for water-containing formulations.
• Reduced residual peroxide and aldehyde impurities.

This strategy can support consumer claims such as fragrance-free or sensitive-skin positioning, subject to regulatory substantiation.

4. Improve packaging and dose delivery

Packaging is an underused differentiation area. A Miconazole 3 product can gain commercial value through:

• Individually wrapped ovules.
• Applicators with improved insertion control.
• Tamper-evident packaging.
• Child-resistant secondary packaging where appropriate.
• Better barrier protection against heat and humidity.
• Compact packaging for discreet storage.
• Applicator-free formats that reduce plastic use.

Packaging changes can also reduce leakage, breakage, and dose variability. They may create patentable subject matter even when the active ingredient and core formulation are old.

What formulations are protected by Miconazole 3 patents?

Miconazole nitrate has been marketed for decades, and the basic active ingredient, conventional vaginal cream, and standard three-day suppository concepts are mature. The principal IP opportunities are therefore more likely to involve formulation details, manufacturing controls, packaging, delivery systems, and brand assets than the active molecule.

Potentially protectable subject matter includes:

• Specific lipid-base compositions.
• Defined melting-point ranges.
• Particle-size distributions.
• Drug-release profiles.
• Bioadhesive vaginal formulations.
• Low-irritation preservative systems.
• Stable emulsions with defined pH and viscosity.
• Applicator geometry.
• Unit-dose packaging.
• Manufacturing processes that reduce polymorphic conversion.
• Combination products containing internal and external treatment components.

A patent claim directed only to “miconazole nitrate in a vaginal suppository” would face substantial validity and prior-art risks. Stronger claims require narrow, measurable limitations tied to improved stability, release, tolerability, manufacturability, or delivery.

When does Miconazole 3 lose exclusivity?

Miconazole 3 does not depend on a conventional branded-drug exclusivity timeline in the way a newly approved prescription product does. The active ingredient and basic vaginal dosage forms are established. U.S. commercial entry is generally controlled by OTC monograph compliance, trademarks, manufacturing capability, retail access, and product quality.

Exclusivity or barrier	Relevance to Miconazole 3
New chemical entity exclusivity	Not applicable to mature miconazole nitrate
Hatch-Waxman exclusivity	Generally not the central market-access mechanism for OTC monograph products
Biosimilar exclusivity	Not applicable
Orange Book listing	Usually not the principal reference for monograph OTC vaginal products
Formulation patents	May apply to specific products or delivery systems
Trademark rights	Important for branded products such as Monistat
OTC monograph compliance	Central U.S. regulatory pathway
Manufacturing and supply rights	Material barrier for private-label entrants

Patent expiration dates must be evaluated at the specific patent-family level. There is no single expiration date that governs all Miconazole 3 products. A party conducting freedom-to-operate analysis should review U.S. composition, formulation, method-of-use, packaging, and process patents, together with terminal disclaimers and patent-term adjustments.

What is the Orange Book status of Miconazole 3?

The Orange Book is primarily designed for approved prescription and certain approved over-the-counter drug products. A monograph-compliant OTC Miconazole 3 product is not necessarily protected by an Orange Book-listed patent in the same way as an NDA product.

The commercial implications are:

• A competitor may not need to file an ANDA to market a compliant OTC monograph product.
• Paragraph IV certification is generally associated with ANDA litigation and is not the normal route for a purely monograph-compliant OTC product.
• A branded product with an NDA or other approved application may have a different patent and exclusivity profile.
• Product-specific patents can still create litigation risk even when the active ingredient is old.

The absence of an Orange Book barrier does not eliminate risk from patents, trademarks, trade dress, confidential manufacturing information, or regulatory noncompliance.

Which companies compete with Miconazole 3?

Competition comes from branded OTC products, store brands, generic-equivalent offerings, and alternative antifungal regimens.

Competitor category	Examples	Competitive variable
Branded miconazole	Monistat 3 and related products	Brand recognition, distribution, advertising
Store-brand miconazole	Retailer and pharmacy private labels	Price and shelf placement
Other miconazole regimens	One-day and seven-day products	Convenience versus tolerability
Clotrimazole	Vaginal creams and tablets	Active ingredient and regimen
Tioconazole	Single-dose vaginal products	Convenience
Prescription azoles	Fluconazole and other therapies	Physician-directed treatment
Non-drug alternatives	Diagnostic and symptom-management products	Consumer pathway and category substitution

The three-day format occupies a middle position. It is more convenient than seven-day treatment and may be perceived as less aggressive or less irritating than a one-day high-dose product. That positioning can support differentiated packaging and patient-experience claims.

What commercial opportunities exist for Miconazole 3?

Private-label and contract manufacturing

Retailers and pharmacy chains can source a compliant three-day product under store brands. Contract manufacturers with suppository molding, cream filling, applicator assembly, and validated stability programs have an advantage.

The most attractive private-label proposition combines:

• Low-cost hydrogenated vegetable oil formulation.
• Multi-site manufacturing capability.
• Flexible packaging formats.
• Retail-ready labeling.
• Supply reliability during seasonal demand.
• Ability to offer both ovule and cream presentations.

Sensitive-use and premium formulations

A premium product can compete through:

• Fragrance-free formulation.
• Reduced-leakage base.
• Lower-irritation preservative strategy.
• Applicator-free ovules.
• Individually wrapped doses.
• Recyclable or reduced-material packaging.
• Combination packs with external symptom-relief cream.

Claims must remain within the permitted OTC labeling framework unless supported through a separate regulatory route.

Geographic expansion

Regulatory requirements differ by jurisdiction. In the European Union, miconazole vaginal products may be regulated as medicinal products under national or harmonized procedures. Canada, Australia, and Latin American markets apply their own requirements for vaginal antifungal products, excipients, labeling, and product classification.

Geographic expansion should focus on:

• Local permitted excipients.
• Pharmacopeial specifications.
• Climatic stability zones.
• Local language labeling.
• OTC versus prescription classification.
• Import and batch-release requirements.
• Local trademark clearance.

Licensing and partnering

Licensing opportunities are strongest for assets that include a defensible delivery or manufacturing advantage. Potential deal structures include:

• Supply agreements for private-label products.
• Regional licenses for branded formulations.
• Co-development of low-irritation or bioadhesive systems.
• Technology licenses for suppository manufacturing.
• Packaging licenses for low-leakage or applicator systems.
• Out-licensing of formulation patents outside the originator’s core markets.

A licensing package is more valuable when it includes formulation know-how, validated analytical methods, stability data, and scalable manufacturing instructions rather than a composition patent alone.

What patent litigation and Paragraph IV risks affect Miconazole 3?

The litigation risk is generally lower for the mature active ingredient than for a novel formulation or delivery system. The main risks are:

• A branded formulation patent asserted against a reformulated entrant.
• Trade dress or trademark disputes involving retail packaging.
• Manufacturing-process infringement.
• Patent claims covering a specific suppository base or release profile.
• Regulatory disputes over whether a product remains within the OTC monograph.
• ANDA-related Paragraph IV litigation if a competitor’s product is marketed through an approved application rather than solely under the monograph pathway.

A generic or private-label entrant should conduct a claim chart against formulation, process, packaging, and use patents. It should also preserve evidence supporting noninfringement, invalidity, and monograph compliance.

How strong is the Miconazole 3 patent estate?

The patent estate for the basic three-day miconazole concept is likely weak because of long commercial use and extensive prior art. The estate can be stronger around narrow technical features.

Asset type	Relative strength
Miconazole nitrate molecule	Low for new exclusivity
Basic 200 mg three-day regimen	Low
Conventional fatty suppository base	Low to moderate
Defined low-leakage formulation	Moderate if supported by data
Bioadhesive or controlled-release system	Moderate to strong, depending on prior art
Novel applicator or package	Moderate
Manufacturing process	Moderate if difficult to design around
Brand and trade dress	Potentially strong for market recognition

Patent strength depends on claim scope, written description, enablement, prior art, prosecution history, and geographic coverage. Commercial value also depends on whether competitors can design around the claims without sacrificing product performance.

Key Takeaways

• Miconazole 3 is a mature three-day vaginal antifungal format centered on miconazole nitrate 200 mg per dose.
• The U.S. opportunity is primarily an OTC monograph and commercial execution opportunity, not a new-chemical exclusivity opportunity.
• Hydrogenated vegetable oil and hard-fat suppository systems offer the most direct development path.
• The strongest differentiation areas are leakage control, local tolerability, drug release, packaging, and applicator design.
• Orange Book exclusivity and biosimilar risk are generally not central to this product category.
• Formulation, process, packaging, and manufacturing patents may still create freedom-to-operate barriers.
• Private-label supply, premium sensitive-use products, regional licensing, and contract manufacturing are the clearest commercial opportunities.
• A basic miconazole three-day formulation is likely difficult to protect broadly; narrow claims supported by performance data have greater value.

FAQs About Miconazole 3 Excipient Strategy

Can miconazole nitrate be formulated without preservatives?

Yes. Anhydrous suppositories can avoid conventional aqueous preservatives. Water-containing creams require a validated microbial-control strategy, which may include preservatives, low water activity, packaging controls, or a preservative-free system supported by testing.

Are hydrogenated vegetable oils suitable for miconazole suppositories?

Yes. They are widely used as suppository bases because they can provide acceptable melting and moldability. Developers must control polymorphism, oxidation, melting-point variation, leakage, and drug release.

Can a new excipient create market exclusivity for Miconazole 3?

An excipient alone rarely creates durable exclusivity. A patent may protect a defined composition, performance range, release profile, manufacturing process, or package that uses the excipient in a non-obvious way.

Is a one-day miconazole product commercially superior to Miconazole 3?

Not universally. One-day products offer convenience, while three-day products may provide a balance between treatment duration, dose intensity, tolerability, and consumer preference. Retail positioning and formulation performance determine the commercial outcome.

Does Miconazole 3 require a Paragraph IV filing to enter the U.S. market?

Not necessarily. A product marketed under the applicable OTC monograph may not use the ANDA pathway that typically generates Paragraph IV certifications. Product-specific patents, approved applications, or other IP rights can still affect launch strategy.

Sources

1. U.S. Food and Drug Administration. (2022). OTC Monograph M030: Vaginal antifungal drug products. https://www.accessdata.fda.gov
2. DailyMed. (2024). Miconazole nitrate vaginal cream and suppository labeling. National Library of Medicine. https://dailymed.nlm.nih.gov
3. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
4. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations. Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
5. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP.